close Icon
  1. Home
  2. Research
  3. Projects
  4. Diagnostic accuracy of Molbio Truenat for diagnosis of TB and rifampicin resistance

Diagnostic accuracy of Molbio Truenat for diagnosis of TB and rifampicin resistance

Tuberculosis (TB) is the second leading cause of death in Papua New Guinea (PNG). GeneXpert MTB/rif a molecular diagnostic for TB has greater sensitivity and specificity than microscopy. However, GeneXpert requires electricity and is costly. New molecular TB diagnostics implementable at the microscopy level are a research priority. There is an urgent need for accurate, battery operated and cheaper TB diagnostics.

The Truenat-MTB/MTB-RIF-Dx reflex assays (Molbio Diagnostics; India) utilise chip-based real-time micro-PCR for detection of TB and rifampicin resistance from samples in 25-120 minutes. They are battery and phone operated devices that can be used in peripheral sites. An accurate point-of-care, portable test such as the Molbio Truenat MTB has the potential to make a significant impact globally, and in countries such as PNG. PNG is one of 4 countries participating in this FIND sponsored multi-country diagnostic accuracy trial, evaluating sensitivity, specificity, and patient important outcomes.

2019 – mid-2020

Square Philipp.Ducros 001 WEB

Doctor Philipp du Cros

Please contact Doctor Philipp du Cros for more information about this project.

EMAIL

Funding
Partners

  • Foundation for Innovative Diagnostics

Partners +
Collaborators

  • PNG Institute of Medical Research,
  • Port Moresby General Hospital,
  • The PNG Central Public Health Laboratory,
  • Victorian Infectious Disease Reference Laboratory,
  • PNG National TB Program

Project
Team

Meet the project team. Together, we are translating research into better health, for all.